Advertisement

Topics

Diseasemodifying drugs - Biotech, Pharma and Life Science Channel

18:17 EST 17th November 2018 | BioPortfolio

PubMed Articles [4453 Associated PubMed Articles listed on BioPortfolio]

First characterizations by capillary electrophoresis of human Chorionic Gonadotropin at the intact level.

In the present work, the first characterizations by Capillary Electrophoresis of the human Chorionic Gonadotropin (hCG) hormone at the intact level were carried out. hCG is a hetero-dimeric glycoprote...

Development of Patient-Derived Tumor Xenograft Models.

In spite of the latest advancements in understanding cancer development and progression, drugs successful in preclinical testing often fail upon reaching phase III clinical trials. A reason for this i...

Image-based Identification of Chemical Compounds Capable of Trapping FOXO in the Cell Nucleus.

Forkhead box O (FOXO) factors are tumor suppressor proteins commonly inactivated in human tumors. Furthermore, genetic variation within the FOXO3a gene is consistently associated with human longevity....

Low rates of Plasmodium falciparum Pfcrt K76T mutation in three sentinel sites of malaria monitoring in Côte d'Ivoire.

Despite efforts to eliminate it, malaria remains a major public health concern, particularly in Côte d'Ivoire. Chloroquine (CQ) was one of the first drugs used for its treatment, but was officially w...

Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections.

In the absence of randomized clinical trial data, questions remain regarding the optimal treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections. CRE have historically been susceptible t...

Clarifying Misconceptions About US Food and Drug Administration Unapproved Drugs Program.

Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis.

Oncolytic virotherapy has been emerging as a promising novel cancer treatment which may be further combined with the existing therapeutic modalities to enhance their effects. To investigate how viroth...

Vigilance demand and the effects of stimulant drugs in a five-choice reaction-time procedure in mice.

Stimulant drugs used for treating attention-deficit hyperactivity disorder (ADHD) increase signal-detection accuracy in five-choice serial reaction-time procedures. These increases may result from dru...

Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy.

Although elevated serum low-density lipoprotein-cholesterol (LDL-C) is without any doubts accepted as an important risk factor for cardiovascular disease (CVD), the role of elevated triglycerides (TGs...

Antileishmanial activity of sulphonamide nanoemulsions targeting the β-carbonic anhydrase from Leishmania species.

The β-carbonic anhydrase (CA, EC 4.2.1.1) from Leishmania spp. (LdcCA) is effectively inhibited by aromatic/heterocyclic sulphonamides, in the low nanomolar range, but no in vitro antileishmanial act...

News Articles [4604 Associated News Articles listed on BioPortfolio]

Obesity can fuel tumour growth by suppressing the immune system’s response to cancer — but it could also render tumours particularly sensitive to certain cancer drugs #ResearchHighlight https://go.nature.com/2QF7TtJ 

Obesity can fuel tumour growth by suppressing the immune system’s response to cancer — but it could also render tumours particularly sensitive to certain cancer drugs #ResearchHighlight ...

New strategy to hinder emergence of antimicrobial-resistant pathogens

With many disease-causing bacteria ratcheting up their shields against current drugs, new tactics are vital to protect people from treatment-resistant infections.

Digital Landscape: Inflammatory Bowel Disease [Report Updated: 06092018] Prices from USD $6000

Digital Landscape: Inflammatory Bowel DiseaseSummaryThe Digital Landscape Inflammatory Bowel Disease report analyzes digital activities undertaken by pharma in support of diseasemodifying therapies fo...

Cellectar Announces Resignation of Chief Medical Officer John Friend

John Friend, vice president and chief medical officer of Cellectar Biosciences (NASDAQ: CLRB), on Tuesday tendered his resignation from the company, Cellectar said in a regulatory filing. Friend’s l...

FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on

NIIMBL Issues Roadmaps For Advancing Gene Therapy, Vaccine And Antibody Drug Conjugate Manufacturing

A public/private manufacturing technology partnership has produced three roadmaps to help the biopharmaceutical industry navigate some of the regulatory and...   

Pfizer to raise prices on 41 drugs in 2019

Drug manufacturer Pfizer announced it would raise the prices of 41 drugs in January 2019, The Wall Street Journal reported.

Pfizer To Raise Prices On 41 Drugs – WSJ https://www.wsj.com/articles/pfizer-to-raise-prices-on-41-drugs-1542398034 …

Pfizer To Raise Prices On 41 Drugs – WSJ https://www.wsj.com/articles/pfizer-to-raise-prices-on-41-drugs-1542398034 …

Series A round brings $30mm to Kymera

Kymera Therapeutics Inc. raised $30mm through its Series A round. Atlas Venture (which co-founded and seeded the company) led the round and was joined by Lilly Ventures and Amgen Ventures. Kymera is d...

SGLT2 inhibitors tied to ketoacidosis, limb amputation in diabetics

An observational study of nearly 35,000 Scandinavian patients with type 2 diabetes (T2D) has found sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of prescription drugs approved by the F...

Events [0 Results]

None

Companies [321 Associated Companies listed on BioPortfolio]

Nexus Pharmaceuticals

Nexus Pharmaceuticals, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less...

Lyndra Therapeutics

Lyndra Therapeutics’ orally administered dosage form is designed to deliver sustained, steady-state release of one or more drugs for up to a week or longer while temporarily ...

Spectrum Pharmaceuticals Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. S...

Incyte

Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced management and discovery ...

Ark Biosciences

Ark Biosciences is a privately held, clinical-stage global biotechnology company with its corporate office located in ZhangJiang Hi-Tech Park in Shanghai, its R&D Center in Suzhou...

Inflazome

Utilizing the scientific expertise of our founders and advisors, Inflazome is leading the way in developing orally available drugs to address clinical unmet needs in inflammatory ...

Inositec

Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly appl...

LEO Pharma

Founded more than 100 years ago, LEO Pharma is an independent, research-based specialty pharmaceutical company committed to the discovery and development of novel drugs for patien...

H.I.G. BioHealth Partners, LLC

H.I.G. BioHealth Partners is the dedicated life-science investment affiliate of H.I.G. Capital. H.I.G. BioHealth Partners invests in a broad range of healthcare opportunities acro...

BASIS Medical Technologies

BASi is a drug discovery and development services company providing contract research services and research instruments and supplies to the world's leading pharmaceutical companie...

Clinical Trials [1672 Associated Clinical Trials listed on BioPortfolio]

An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs

Post-marketing surveillance study to evaluate the real world safety and effectiveness of Maviret (Glecaprevir/Pibrentasvir) administered under a normal, routine treatment practice by Korea...

CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma

This phase I trial studies best dose and side effects of CBL0137 in treating patients with extremity melanoma or sarcoma that has spread to other places in the body. Drugs, such as CBL0137...

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

This phase Ib trial studies the side effects and best dose of ALRN-6924 when given together with paclitaxel in treating patients with solid tumors that have spread to other places in the b...

Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

SHR-1603-I-101 is an single-arm, open-label, dose finding phase I clinical trial of SHR-1603 in subjects with advanced solid tumor or relapsed/refractory malignant lymphoid diseases. The s...

Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs

The study assesses PK and safety of other drugs, such as some antibiotics, proton pump inhibitors, statins, and combined oral contraceptives when co-administered with Elpida®

Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs

This is open label, phase 1 clinical study to evaluate the safety, tolerability and pharmacokinetics of Elpida® in healthy subjects and patients with hepatic impairment (Child - Pugh Clas...

Ropivacaine 0,2% Plus Dexamethasone Versus Ropivacaine 0,2% Plus Placebo in Modified Pectoral Block

To find out if dexamethasone used as adjuvant to ropivacaine, a long-lasting local anesthetic, prolongs the duration of modified pectoral nerve block in women undergoing breast surgery.

Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage

Haemorrhagic stroke, an emergency caused by bleeding in the brain, often leads to death or long-term disability. A quarter of these patients are taking blood-thinning drugs (antiplatelet d...

Stigma, Risk Behaviors and Health Care Among HIV-infected Russian People Who Inject Drugs

This study is a randomized controlled trial (RCT) among 100 HIV-positive people with injection drug use, which aims to test the feasibility of the SCRIPT intervention and evaluate its effe...

The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children

Vasculitis denotes affection of small to medium sized vessels by polyangitis. Antineutrophil cytoplasmic antibodies (ANCA) are immunoglobulin G (IgG) autoantibodies directed against consti...

Videos

None available.

Medical and Biotech [MESH] Definitions

Drugs used by veterinarians in the treatment of animal diseases. The veterinarian's pharmacological armamentarium is the counterpart of drugs treating human diseases, with dosage and administration adjusted to the size, weight, disease, and idiosyncrasies of the species. In the United States most drugs are subject to federal regulations with special reference to the safety of drugs and residues in edible animal products.

Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.

The use of multiple drugs administered to the same patient, most commonly seen in elderly patients. It includes also the administration of excessive medication. Since in the United States most drugs are dispensed as single-agent formulations, polypharmacy, though using many drugs administered to the same patient, must be differentiated from DRUG COMBINATIONS, single preparations containing two or more drugs as a fixed dose, and from DRUG THERAPY, COMBINATION, two or more drugs administered separately for a combined effect. (From Segen, Dictionary of Modern Medicine, 1992)

Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here.

Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.

Advertisement
Quick Search
Advertisement
Advertisement

 
review and buy Diseasemodifying drugs market research data and corporate reports here

Channels Quicklinks